Skip to main content
main-content

Zeitschrift

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology 6/2020

Ausgabe 6/2020

Inhaltsverzeichnis ( 17 Artikel )

31.05.2020 | Editorial | Ausgabe 6/2020

NUC-1031 in biliary tract cancer: from bench to bedside and back?

Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti

18.05.2020 | Review Article | Ausgabe 6/2020

Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs

Wenying Angela Liu, Li Yu, Peter N. Morcos, Francois Mercier, Barbara J. Brennan

22.04.2020 | Original Article | Ausgabe 6/2020

Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil

Yoshiaki Fujimoto, Ryota Nakanishi, Mamoru Nukatsuka, Kazuaki Matsuoka, Koji Ando, Takeshi Wakasa, Hiroyuki Kitao, Eiji Oki, Yoshihiko Maehara, Masaki Mori

11.05.2020 | Original Article | Ausgabe 6/2020 Open Access

In vivo assessment of the drug interaction between sorafenib and paracetamol in rats

Agnieszka Karbownik, Katarzyna Sobańska, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Anna Wolc, Edmund Grześkowiak, Edyta Szałek

15.05.2020 | Original Article | Ausgabe 6/2020

The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats

Haitao Chen, Chao Xu, Fan Zhang, Yu Liu, Yong Guo, Qinghua Yao

21.05.2020 | Original Article | Ausgabe 6/2020

Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer

Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Mark J. Truty, Mitesh J. Borad

22.05.2020 | Original Article | Ausgabe 6/2020

MEK inhibition overcomes everolimus resistance in gastric cancer

Hongfang Liu, Yang Yao, Juan Zhang, Jing Li

23.05.2020 | Original Article | Ausgabe 6/2020

A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors

Tracy Murray Stewart, Apurva A. Desai, Michael L. Fitzgerald, Laurence J. Marton, Robert A. Casero Jr.

24.05.2020 | Original Article | Ausgabe 6/2020

Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway

Songbin Guo, Jinling Zhang, Cairong Wei, Zhiyong Lu, Rulong Cai, Danqi Pan, Hanbin Zhang, Baoxia Liang, Zhenfeng Zhang

24.05.2020 | Original Article | Ausgabe 6/2020

Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

Ken Ogasawara, William B. Smith, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna

26.05.2020 | Original Article | Ausgabe 6/2020

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients

Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Masae Sekido, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Toshikazu Ikusue, Kouji Kobayashi, Atsushi Hisamatsu, Hirokazu Toshima, Ken Shimada, Ken-ichi Fujita

28.05.2020 | Original Article | Ausgabe 6/2020

Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents

Guangan He, Xiaolei Xie, Zahid H. Siddik

29.05.2020 | Original Article | Ausgabe 6/2020 Open Access

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer

Anabel Beatriz Sanchez-Spitman, Dirk-Jan A. R. Moes, Jesse J. Swen, Vincent O. Dezentjé, Diether Lambrechts, Patrick Neven, Hans Gelderblom, Henk-Jan Guchelaar

30.05.2020 | Original Article | Ausgabe 6/2020

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

Mandy Juarez, Alejandro Schcolnik-Cabrera, Guadalupe Dominguez-Gomez, Alma Chavez-Blanco, Jose Diaz-Chavez, Alfonso Duenas-Gonzalez

31.05.2020 | Original Article | Ausgabe 6/2020

In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients

Jeerawan Klangjorhor, Areerak Phanphaisarn, Pimpisa Teeyakasem, Parunya Chaiyawat, Phichayut Phinyo, Jongkolnee Settakorn, Nipon Theera-Umpon, Dumnoensun Pruksakorn

16.05.2020 | Short Communication | Ausgabe 6/2020

CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model

J. H. Azambuja, R. S. Schuh, L. R. Michels, N. E. Gelsleichter, L. R. Beckenkamp, G. S. Lenz, F. H. de Oliveira, M. R. Wink, M. A. Stefani, A. M. O. Battastini, H. F. Teixeira, E. Braganhol

10.04.2020 | Expression of Concern | Ausgabe 6/2020

Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells

Hongjian Yang, Yue Lu, Yabing Zheng, Xingfei Yu, Xianghou Xia, Xiangming He, Weiliang Feng, Lei Xing, Zhiqiang Ling

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise